v3.10.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Current assets    
Cash and cash equivalents $ 9,435 $ 12,821
Accounts receivable 60,765 60,427
Inventories 6,898 7,474
Other current assets 6,161 5,153
Total current assets 83,259 85,875
Property and equipment (net of accumulated depreciation of $45,678 and $40,530, respectively) 42,873 36,504
Intangible assets, net 71,330 74,165
Goodwill 147,019 147,019
Other assets 1,302 891
Total assets 345,783 344,454
Current liabilities    
Accounts payable 12,337 10,450
Accrued compensation 11,184 9,482
Accrued expenses and other liabilities 9,889 6,144
Short-term portion of capital leases and car loans 5,847 5,239
Short-term portion of loans 6,562 3,750
Pharma contract liability 2,155 1,406
Total current liabilities 47,974 36,471
Long-term liabilities    
Long-term portion of capital leases and car loans 5,414 5,303
Long-term portion of loans, net 91,535 66,616
Revolving credit facility, net 29,176 24,516
Long-term pharma contract liability 648 283
Deferred income tax liability, net 6,827 6,688
Total long-term liabilities 133,600 103,406
Total liabilities 181,574 139,877
Commitments and contingencies
Redeemable convertible preferred stock    
Series A Redeemable Convertible Preferred Stock, $0.001 par value, (50,000,000 shares authorized; 0 and 6,864,000 shares issued and outstanding) 0 32,615
Stockholders' equity    
Common stock, $0.001 par value, (250,000,000 shares authorized; 81,632,045 and 80,462,574 shares issued and outstanding, respectively) 81 80
Additional paid-in capital 217,451 230,030
Accumulated other comprehensive income 257 274
Accumulated deficit (53,580) (58,422)
Total stockholders’ equity 164,209 171,962
Total Liabilities and Stockholders' Equity $ 345,783 $ 344,454

Source